Radiofrequency Ablation vs Sham Procedure for Symptomatic Cervical Inlet Patch

Barrett Esophagus Clinical Trial

Official title:

Randomised Controlled Trial of Radiofrequency Ablation Versus a Sham Procedure for Symptomatic Cervical Inlet Patch

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03471052
• Other study ID #: 216038
• Status: Recruiting
• Phase: N/A
• Start date: March 6, 2018
• Est. completion date: September 30, 2021

Study information

• Verified date: February 2020
• Source: Guy's and St Thomas' NHS Foundation Trust
• Contact: Jason Dunn
• Phone: 02071887188
• Email: GMSresearch[@]gstt.nhs.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Inlet patch is a congenital condition of the upper oesophagus, consisting of stomach lining that is in the wrong place. It affects 5% of the population. Symptoms are a feeling of a ball in the back of the throat (called chronic globus sensation), cough and sore throat - these account for 4% of general practitioner (GP) referral to Ear Nose & Throat departments.

There is no recognised treatment. Drugs that reduce acid may help but do not block mucus production. Argon Plasma coagulation has been shown to be successful but limited to a few expert centres. The investigators have previously shown a device that uses radiofrequency energy to remove the patch to be highly effective in a ten patient pilot study, with 80% response rate that was durable over 1 year.

The purpose of this trial is to demonstrate the previous study was not due to placebo effect alone, with a sham controlled arm. Patients would then crossover to treatment at 6 months after sham. All males and non-pregnant females over 18 years old with previously diagnosed inlet patch causing symptoms of globus, with > 50% severity on a visual analogue score, are eligible.

Description:

Inlet patch is a congenital anomaly of the upper oesophagus, consisting of stomach lining that is in an aberrant position. Prevalence is up to 10% on endoscopy studies and 5% on post mortem studies. There is thought to be a link with another condition of the lower oesophagus called Barrett's oesophagus, although there is limited evidence. Unlike Barrett's oesophagus, progression to cancer from an inlet patch is exceptionally rare.

The inlet patch can produce acid and mucus, and is associated with symptoms including sore throat, cough and hoarseness. One particular symptom, called globus pharyngeus (the feeling of a ball in the back of the throat) is often associated with an inlet patch.

There is no recognised treatment for symptomatic inlet patch. Anti-acid medications works for some but not all, which may in part be explained by the lack of acid producing cells in some inlet patches. Ablation of the inlet patch has been successful in small series using Argon Plasma Coagulation. This device is, however, associated with inter user variability and unpredictable depth of ablation. Radiofrequency ablation (RFA) using the BarrxTM System is a National Institute for Health and Clinical Excellence (NICE) and FDA approved device for treatment of abnormal oesophageal lining, which has shown to be successful in reversing Barrett's oesophagus to normal squamous lining. These devices are advantageous as the depth of ablation is controlled. The investigators have previously demonstrated, in a pilot study, that these devices are safe and effective for reversal of inlet patch to normal mucosa, with improvement in symptoms.

This study will use the BarrxTM system to treat patients with symptomatic inlet patch that is refractory to standard anti-acid medication, in a blinded sham controlled trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: September 30, 2021
• Est. primary completion date: January 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with symptoms secondary to Inlet patch and globus score > 50 on Visual Analogue Scale (VAS)

2. Histological confirmation of presence of Inlet patch

3. Symptoms not responsive or partially responsive to (proton pump inhibitor) PPI therapy for > = 6 weeks

4. Males and non-pregnant females over the age of 18 years. Female patients who are pre-menopausal must practice a medically acceptable form of contraception.

5. Patients must sign an informed consent form.

Exclusion Criteria:

1. Patients in whom endoscopy is contraindicated.

2. No globus symptoms

3. Patients previously or currently treated for oesophageal dysplasia or cancer

4. Patients with eosinophilic oesophagitis

5. Patients with oesophageal varices

6. Previous radiotherapy

7. Patients who have undergone Hellers myotomy

8. Pregnant females.

9. People under the age of 18 years.

10. Evidence of major motility disorder on High resolution Manometry

11. Patients with pre-existing ENT disorders causing globus.

Related Conditions & MeSH terms

• Barrett Esophagus

Intervention

Procedure:
• Radiofrequency ablation (RFA)
Ablation using the Barrx RFA System is a new technique for field ablation in the oesophagus. It has been used for eradication of diseased epithelium of all three subclasses of Barrett's oesophagus (non-dysplastic Intestinal metaplasia (IM), Low grade dysplasia (LGD) and High grade dysplasia (HGD). The BarrxTM RFA System uses ultra short pulse RF energy delivering 40Watts/cm2 power density and 12Joule/cm2 energy density, and affects the mucosa whilst preserving the submucosa. Clinical trials have suggested that it is safe and effective for treating non-dysplastic IM, LGD and HGD in Barrett's oesophagus . Long term data show the effect to be durable over 5 years.

Locations

Country	Name	City	State
United Kingdom	Guy's and St Thomas' NHS Foundation Trust	London

Sponsors (1)

Lead Sponsor	Collaborator
Guy's and St Thomas' NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in globus symptoms	>50% reduction in globus as assessed by improvement in patient symptom scoring	6 months post ablation
Primary	Endoscopic eradication of inlet patch	Eradication of inlet patch as assessed by endoscopic investigation	Change from 6 months to 12 months post final ablation
Primary	Histological reversal to squamous mucosa	Complete histological reversal to squamous mucosa as assessed by histological staining of the biopsy samples	Change at 6 and 12 months
Primary	Change in surface area of residual inlet patch post ablation	Change in surface area of residual inlet patch post ablation	Change at 6 and 12 months
Secondary	Oesophageal pH pre and post ablation	Oesophageal pH pre and post ablation	Change at Pre-screening and 12 months
Secondary	Adverse events	Adverse event incidence at any time during the study	Through study completion, an average of 12 months
Secondary	Presence of buried mucosa consistent with inlet patch	Presence of buried mucosa consistent with inlet patch	During endoscopy
Secondary	Symptomatic response for cough, hoarseness and sore throat using Visual Analogue Scale (VAS)	Symptomatic response for cough, hoarseness and sore throat using VAS	Through study completion, an average of 12 months